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UM-UC-3The mechanisms that underlie tumor formation and progression have not been elucidated in detail in cancer
biology. Recently, the identiﬁcation of a tumor cell subset deﬁned as cancer stem cells (CSCs), which is enriched
for tumor initiating capacity, has engendered new perspectives towards selective targeting of tumors. In this
study, we isolated the side population (SP) cells which share characteristics of CSCs from bladder cancer cell
lines, T24 and UM-UC-3 by ﬂuorescence activated cell sorting. The cells were cultured in serum free medium
and expression proﬁle of stem cell like markers (SOX-2, NANOG, KLF-4 and OCT-4), drug resistant genes
(ABCG2 and MDR1) and spheroid forming capability were examined in SP, non-side population (NSP) and
bulk T24 and UM-UC-3 cells. We observed that SP cells possessed a higher mRNA expression of SOX-2,
NANOG, KLF-4, OCT-4, ABCG2, and MDR1 as well as a higher spheroid forming ability as compared to other
bulk cells or NSP cells. The SP cells had low ROS levels and high GSH/GSSG ratio which may contribute to
radio-resistance. The SP cells also showed substantial resistance to gemcitabine, mitomycin and cisplatin com-
pared with the NSP counterpart. A high autophagic ﬂux was observed in the SP cells. Both pharmacological
and siRNA mediated inhibition of autophagy potentiated the chemotherapeutic effects of gemcitabine, mitomy-
cin and cisplatin in these cells. We concluded that the ABCG2 expressing SP cells show autophagy associated cell
survival and may be a potent target for developing more effective treatment in bladder carcinoma to enhance
patient survival., +91 9876186816 (Mobile);
haryya).© 2014 Elsevier B.V. All rights reserved.1. Introduction
Human solid tumors and clonal tumor cell lines comprise phenotyp-
ically and functionally diverse subsets of cells. Cancer stem cells (CSCs),
discovered recently in several solid tumors, represent a cell-population
that can survive treatment and repopulate the tumor. These cells may
play a unique role in tumor maintenance, by virtue of resistance to
chemotherapeutic agents and radiation [1]. CSCs share some character-
istics with adult stem cells like unlimited capacity for proliferation, self-
renewal and ability to differentiate to other cell types [2]. Various
surface markers selectively expressed on CSCs have been identiﬁed
and are used to isolate these cells, however in many tumor types no
marker or pattern of marker is known to prospectively identify CSCs.
In such cases, exploitation of stem cell characteristics can be used to
identify CSCs. One such characteristic is the ability of side population
(SP) cells to exclude dyes such as Hoechst 33342. CSCs have been
identiﬁed in immortalized cell lines, long-term cultured cancer cellsand patient tumor samples using theﬂow-cytometry based SP technique
[3]. The expression of ATP-binding cassette efﬂux transporter ABCG2 by
SP cells is thought to confer themwith intrinsic resistance to many anti-
tumor agents [4]. Thus, this subset of cancer cells may be an important
target for therapeutic interventions, preventing chemo-resistance and
cancer relapse.
Urothelial carcinoma (UC) or bladder cancer is the most common
cancer of the urogenital tract. Majority of deaths in bladder cancer are
due to unresectable lesions that are resistant to chemotherapy [5].
Despite improvement in radiation and chemotherapy regimens, there
have been few advances in the design of treatment strategies for
chemotherapy-resistant UC. The therapeutic resistance and recurrence
in patientswith UCmay be attributed to the presence of CSC population.
The identiﬁcation of a cancer stem cell like population in the SP in blad-
der cancer may provide new therapeutic approaches in research
targeting these malignant cells.
Recent evidences indicate that autophagy acts as a cell survival
mechanism in bladder cancer as a whole [6] and may be associated
with multiple cancer related pathways including chemo-resistance [7].
We showed the critical role of autophagy in SP cell tumorigenicity by
chemical inhibition of autophagy and silencing of Beclin1 (BECN1),
the mammalian ortholog of the yeast apg6/vps30p which is required
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suppressor gene that is monoallelically deleted or shows reduced
expression in various cancers [8]. Recently, many studies have shown
that several types of tumor cells depend on autophagy for growth in
normal condition [9,10]. Therefore, we investigated whether autophagy
might be involved in the survival of SP cells in bladder cancer cell lines.
As tumor grows, areas of nutrient and oxygen deprivation (hypoxia)
arise due to inadequate blood supply [11]. Hypoxia leads to induction of
pro-angiogenic factors and down-regulation of anti-angiogenic factors
[12]. It is known that hypoxia inducible factor (HIF1) induces vascular
epithelial growth factor (VEGF) which is correlated to tumor progres-
sion and metastasis. Tumor hypoxia and angiogenesis may provide
therapeutic resistance to anticancer agents, increase in invasion, metas-
tasis and poor outcome inmalignancies [13]. Hypoxia, nutrient depriva-
tion and angiogenesis are known to induce the autophagy [14]. Hypoxia
also triggers an acute induction of reactive oxygen species (ROS) over a
short period of time, while prolonged hypoxia results in decreased in-
tracellular ROS levels as compared to normoxia [15]. The biological
role of ROS in CSC subpopulation is still not clear though ROS regulation
has been studied in cancer cells as a whole. Our hypothesis is that lowFig. 1. Identiﬁcation and characterization of side population (SP) in T24 cells. (A) T24 cells
were stained with Hoechst 33342 dye (5 mg/ml) in the presence (right) or absence (left)
of 50 mol/l verapamil and analyzed by ﬂow-cytometry. The quantiﬁcation of SP as in
(A) carried out with FACS Diva software is shown in lower panel. (B) Immuno-staining
of CD44 and pancytokeratin in sorted SP and non-side population (NSP) cells under con-
focal microscope (60× magniﬁcation). Each experiment was repeated three times. All
values are expressed as mean ± SEM.ROS levels during proliferation protects these cells against DNA damage
and facilitates tumor propagation. Several studies show that autophagy
is involved in both degradation and formation of ROS [16]. Autophagy
mediated support of tumor cell survivalmay play a critical role in cancer
progression at later stages, such as dissemination andmetastasis, which
account for most cancer-associated deaths.
In this study, we isolated and characterized the SP cells from two
bladder cancer cell lines, T24 and UM-UC-3. These cells showed higher
resistance to chemotherapeutic agents like gemcitabine, mitomycin
and cisplatin compared to the cells in non-side population (NSP). Our
results suggested that autophagy contributed to the ability of the SPFig. 2. The expression of stemness and drug resistant genes in T24 SP cells. (A) Reverse
transcriptase PCR analysis for stemness genes (SOX-2, OCT-4, KLF-4 and NANOG) and
drug resistant genes (ABCG2 andMDR1). Densitometrywas performed using ImageJ soft-
ware and fold change was calculated by normalizing with the house keeping gene ACB.
The results are shown as bar graphs in the lower panel. (B) The bar graph shows the
percentage of cell death in SP and NSP at 24 h with cisplatin/gemcitabine/mitomycin. Un-
treated cells in culture media were taken as control. Each experiment was repeated three
times. All values are expressed asmean±SEM. *, p b 0.05NSPvs. SP. **, p b 0.01NSPvs. SP.
NSP = non side population; SP = side population.
Fig. 3. ROS generation in T24 SP cells. (A) Fluorescent microscopy images of cells (SP, NSP and bulk T24 cells) stained with DCFH-DA (20× magniﬁcation). The lower panel shows the
quantiﬁcation data. All values are expressed as mean ± SEM. *p b 0.05 bulk-T24/NSP vs. SP. (B) Ratio of GSSG to GSH in SP and NSP shown in different time intervals. Each experiment
was repeated three times. All values are expressed as mean ± SEM. *p b 0.05 NSP vs. SP.
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population, leading to relapse. Hence, targeting autophagy in bladder
cancer SP cells may provide a novel approach for a more effective
treatment.2. Materials and methods
2.1. Cell culture and reagents
T24 bladder cancer cell line was procured from the National Centre
for Cell Sciences, Pune, India and cultured in the RPMI-1640 media
[Sigma (St. Louis, MO)] containing 10% fetal bovine serum (FBS)
[Sigma (St. Louis, MO)]. UM-UC-3 cell line (a kind gift from Dr. Sekhar
Majumdar, IMTECH, Chandigarh, India) was originally procured from
the European Collection of Cell Culture and maintained in RPMI-1640
media with 10% FBS. The monoclonal anti-CD44, pan-cytokeratin,
caspases-12, -3, -8 and -9, cytochrome-c antibodies and secondary ﬂuo-
rochrome conjugated antibodies were obtained from BD Biosciences
(San Diego, CA). Monoclonal antibodies against LC3, Beclin1, Atg7 and
p62 were purchased from Cell Signaling Technology (Carpinteria, CA).
Antibodies against Bax, Bcl-2, c-IAP-1 and c-IAP-2 were purchased
from Santa Cruz Technology (Santa Cruz, CA). Anti-Bim antibody was
purchased from BD Biosciences (San Diego, CA). Anti-rabbit, mouse
and goat secondary-IgG antibodies were purchased from Cell Signaling
Technology (Carpinteria, CA). BECN1-siRNA and control-siRNA were
obtained from Santa Cruz Technology. Anti-XIAP antibodywas obtainedfrom Abcam (San Diego, CA). All other chemicals were obtained from
Sigma (St. Louis, MO) unless speciﬁed otherwise.
2.2. Side population analysis
Side population was isolated according to the method of Goodell
et al. [17] with some modiﬁcations. Brieﬂy, cells (1 × 106 cells/ml)
were taken in pre-warmed RPMI-1640 containing 5% FBS and incubated
with Hoechst 33342 (5 mg/ml) for 90 min at 37 °C in a water bath. In
another set of experiments, cells were incubated with the Hoechst dye
(5 mg/ml) in the presence of verapamil (50 μmol/ml). At the end of
incubation, propidium-iodide (PI, 2 μg/ml) was added and an analysis
was done on a BD FACS Aria-II ﬂow-cytometer. The Hoechst dye was
excited with the UV laser at 351 to 364 nm and its ﬂuorescence was
measured with a 515 nm side population ﬁlter (Hoechst blue) and a
608 optical ﬁlter (Hoechst red).
2.3. Immuno-staining
Cells (1 × 104) were seeded on cover-slips in six-well culture plates
and treated with HBSS/antimycin/tunicamycin/chemotherapeutic
agents (cisplatin/gemcitabine/mitomycin) in separate experiments.
After treatment, cells were washed with 1× PBS and ﬁxed in 4% para-
formaldehyde, thereafter permeabilized with 0.1% Triton X-100. Cells
were blocked with 5% BSA for 2 h and incubated with the primary anti-
bodies for 5 h at room temperature. Subsequently, cells were washed
with 1× PBS and incubated with FITC or PE labeled secondary
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again washed with 1× PBS and stained with Hoechst for nuclear stain-
ing and analyzed under confocal microscope (Olympus, 1 × 81). Punc-
tates of LC3 were counted in FLUOVIEW (FV1000-FV10-ASM)
software (Olympus).
2.4. Sphere formation assay
FACS-sorted SP cells were plated in ultra-low attachment six well
plates in serum-free keratinocyte medium supplemented with growth
factors (1:50, Invitrogen), 20 ng/ml epidermal growth factor (BD Biosci-
ences, San Diego, CA), 0.4% FBS [Sigma (St. Louis, MO)] and 4 mg/ml in-
sulin [Sigma (St. Louis, MO)] as described previously [18]. The primary
spheroids were enzymatically dissociated with 0.1% trypsin for 3 min
at 37 °C to obtain a single cell suspension which were then re-
cultured in conditioned medium to produce the next generation of
spheroids.
2.5. Reverse transcriptase PCR analysis
Total cellular RNAwas extracted from freshly sorted SP and non-side
population (NSP) cells using RNA isolation kit (Roche). The purity of the
RNA was checked using a Bio-photometer plus (Eppendorf). RNA was
reverse transcribed with iScript™ cDNA synthesis kit from Bio-RAD
according to the manufacturer's protocol. PCR was done by standard
method [19]. The PCR sequences are provided in Supplementary
Table 1. The PCR products were analyzed by electrophoresis on 2% aga-
rose gel and bands were visualized in Chemidoc-XRS+ (Bio-RAD).
Levels of expression were normalized with β-actin (ACTB). Densitome-
try was performed using NIH ImageJ software.Fig. 4. Spheroid forming capability of T24 SP cells. (A) Lightmicroscopy images of tumorisphere
cells on 3rd, 6th and 9th days was larger as compared to that formed by the NSP cells (scale ba
those obtained from NSP. Each experiment was repeated three times. All values are expressed2.6. Immuno-blot analysis
For Western blot analysis, cell lysates were prepared in RIPA buffer
containing Tris–HCl (50 mM), NP-40 (1%), sodium-deoxycholate(0.25%),
NaCl (150 mM), and EDTA (1 mM). Protein concentration was deter-
mined by BCA assay kit [Sigma (St. Louis, MO)]. Samples were resolved
in SDS-PAGE, transferred to PVDF membrane and analyzed separately.
The blots were probed with one of the primary antibodies of caspase-
3, PARP, Beclin1, Atg7, LC3, XIAP, c-IAP1/2, Bcl-2, Bcl-XL, Bax and
cytochrome-c. Chemiluminescence detection was done with
AmershamECLplusWestern blotting detection system (GE healthcare).
We used peroxidase conjugated anti rabbit-IgG/anti-mouse-IgG/anti-
goat-IgG as secondary antibodies. The band intensity was measured
by Chemidoc-XRS + (Bio-RAD) and quantiﬁcation was done by using
NIH ImageJ software. Densitometric analysis was performed by ImageJ
software.2.7. ROS measurement
Levels of ROS in the various cell populations was bymeasured using
the 2′,7′-dichloroﬂuorescein diacetate (DCFH-DA, 5 μmol/l) [Sigma
(St. Louis, MO)] stain under the ﬂuorescence microscope (Olympus 1
× 51) according to the previously described protocol [20].2.8. GSSG/GSH ratio measurement
GSSG/GSH ratiowasmeasured by colorimetric assay kit (OxiSelect™
Total Glutathione (GSSG/GSH) Assay Kit, STA-312) according to the
manufacturer's protocol.s formed by SP cells in serum-free keratinocytemedium. (B) Size of spheroids formed by SP
r—70 μm). (C) The number of sphere formed/1000 SP cells was signiﬁcantly greater than
as mean ± SEM. ***, p b 0.001 SP vs. NSP.
Fig. 5. Increased autophagy response in SP of T24 cells. (A)Cells were incubated in complete or starvationmedia for 24 h. Representative images of cells showing autophagosomes stained
with MDC in T24, NSP and SP cells captured by ﬂuorescent microscope with UV ﬁlter (20× magniﬁcation). The lower panel shows the quantiﬁcation of the mean ﬂuorescent intensity of
MDC staining as calculated by ImageJ software. (B) Confocal images show immuno-staining of LC3 under the same conditions (60× magniﬁcation). The lower panel shows the number
of LC3 dots/micrograph as calculated by FLUOVIEW (FV1000-FV10-ASM) software. (C) Fluorescent micrographs show MDC staining in the presence of rapamycin (20 nmol/l) and CQ
(50 μM) in SP andNSP cells. Quantitation of themean ﬂuorescent intensity in SP and NSP cells is shown in the lower panel. (D) Fluorescent images of AO/EtBr staining at 24 h of treatment
in SP and NSP cells. Green cells indicate viable healthy cells and orange/red cells represent apoptotic cells. Bar graph shows the percentage of cell death measured byMTT assay at 24 h of
treatment with rapamycin and CQ. (E) Immuno-blot analysis of autophagy proteins with antimycin/tunicamycin at 24 h showed an increased expression of Beclin1, Atg7 and p62. The
lower panels show the relative quantitation of the autophagy proteins, Beclin1, Atg7 and p62 after normalization with actin expression. (F) Confocal images of SP cells treated with
antimycin/tunicamycin and immuno-stained with antibodies against LC3 and TOM (upper panel)/calreticulin (lower panel) at 24 h (60× magniﬁcation). Each experiment was repeated
three times. C = control or untreated cells, T = tunicamycin, A = antimycin. Values are expressed as mean ± SEM. *, p b 0.05 control vs. treatment; **, p b 0.01 control vs. treatment.
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Fig. 5 (continued).
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Cells (1 × 103) were seeded on cover-slip in six-well culture plates
and incubated separately with selected doses of cisplatin/gemcitabine/
mitomycin for 24 h. After treatment, cells were washed with 1× PBS
and stained with acridine orange at a ﬁnal concentration of 1 μg/ml
for a period of 15 min in the dark on ice. Autophagosome formation
was monitored by ﬂuorescence microscopy (Olympus 1 × 15) in blue
ﬁlter. Intensity of AO stain was calculated by ImageJ software.2.10. Monodansyl-cadaverin (MDC) staining
Cells (1 × 103) were seeded on cover-slip in six-well culture plates
and treated with HBSS media for 24 h with or without wortmannin
(Wm, 200 ng/ml), a class III phosphoinositide 3-kinase (PI3K) inhibitor
which inhibits initial stages of autophagy. Cells were washed with 1×
PBS at the end of treatment period and incubated with MDC (0.05
mM) for 10 min in the dark on ice. Cells were washed with 1× PBS
following incubation and immediately analyzed under ﬂuorescencemi-
croscope in UV ﬁlter (Olympus 1 × 51). The intensity of MDC stain was
calculated by ImageJ software.2.11. Cell viability assay
Cell viability was measured by MTT assay [Sigma (St. Louis, MO)]
according to the manufacturers' protocol. Brieﬂy, 2 × 103 cells were
treatedwith cisplatin/gemcitabine/mitomycin for indicated time points
and concentrations. At the end of treatment incubation, 20 μl of MTT
(5 mg/ml in PBS) was added and cells were further incubated for 4 h.
Formazan crystals formed were dissolved in 100 μl of lysis solution
(20% sodium dodecyl sulfate, 50% dimethyl formamide). The absor-
bance of solubilized formazan was read at 570 nm using ELISA reader
(Bio-TEK, synergy-2).2.12. Sub-G1 analysis
Cells (2 × 103) were treated with cisplatin/gemcitabine/mitomycin
for 24 h and apoptosis was determined by measuring the hypoploidy
of DNA. After incubation, cells were trypsinized and washed twice
with 1× PBS, ﬁxed in 90% ethanol for overnight in−20 °C. Thereafter,
cells were washed twice with 1× PBS and stained with PI/RNase stain-
ing buffer (5 μg/ml PI, 200 μg/ml RNase). The percentage of apoptotic
cells was determined by measuring the fraction of nuclei with a sub-
Fig. 5 (continued).
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FACS-Calibur with Cell Quest software (Becton Dickinson).
2.13. Determination of cell death by AO/EtBr assay
T24 and UM-UC-3 cells were seeded and treated with rapamycin
either alone or in combination with autophagy inhibitor for 24 h. After
incubation cell morphology was investigated by staining cells with a
combination of ﬂuorescent DNA binding dye acridine orange (AO)/
ethidium bromide (EtBr). The solution containing each dye at 1 μg/ml
in PBS was mixed 1:1 with cell suspension. Stained cells were viewed
under Olympus ﬂuorescence microscope (20× magniﬁcation). The via-
ble cells take up AO and appeared green, in contrast dead cells take up
EtBr and appeared orange/red.
2.14. Annexin/7-AAD staining
T24 and UM-UC-3 cells were treated with gemcitabine/mitomycin/
cisplatin, either alone or in combination with BECN1-siRNA for 24 h.
Cells were harvested, washed and stained with 5 μl of ﬂuorescein iso-
thiocyanate (FITC)-conjugated annexin-V using Annexin-V staining kit
(BD Pharmingen™) according to the manufacturer's protocol. Stainedcells were immediately analyzed with a Becton Dickinson FACS Aria-II.
The cell population analysis was done by using FlowJo (Tree Star Inc.,
Ashland, OR). The cytograms of the four quadrants was used to distin-
guish the normal (annexin V−/7-AAD−), early apoptotic (annexin V+/
7-AAD−), late apoptotic (annexin V+/7-AAD+), and necrotic (annexin
V−/7-AAD+) cells. The sum of early apoptosis and late apoptosis was
presented as total cell death.
2.15. BECN1 knockdown using small interfering RNA (siRNA)
T24 cells were transfectedwith BECN1-siRNA using Lipofectamine™
2000. The control siRNA was transfected under identical conditions. To
determine the efﬁciency of BECN1 knockdown, Western-blot analysis
for BECN1 was performed. T24 and UM-UC-3 cells (1 × 106) were
transfected with 70 nM siRNA for 6 h, after transfection of cells with
siRNAs, RPMI-1640 without FBS, penicillin and streptomycin was
added for 4 h. Thereafter, fresh RPMI-1640 containing 10% FBS without
penicillin and streptomycin media was added. Following 24 h, chemo-
therapeutic agents were administrated for 24 h in complete media
and cell lysates were prepared for Western blot analysis.
2.16. Statistical analysis
All experiments were performed in triplicate and repeated thrice.
Data were expressed as mean ± SEM and compared using one way
analysis of variance. p b 0.05 was considered as statistically signiﬁcant.
3. Results
3.1. Identiﬁcation and characterization of side population in bladder cancer
In the absence of verapamil, P3 gate showed 5.2% (Fig. 1A) SP cells
thatwere Hoechst 33342 positive. However, on pre-incubationwith ve-
rapamil the percentage of these cells dropped to 0.2 ± 0.03%. The P4
gate indicated the NSP cells (Fig. 1A). In UM-UC-3 cells (a muscle inva-
sive bladder cancer cell line), P3 gate showed 7.9% SP in the absence of
verapamil. The percentage of SP cells dropped to 2.4 ± 0.013% on pre-
incubation with verapamil (Sup Fig. 1A). SP (P3) and NSP (P4) cells
were collected after cell sorting under sterile condition for subsequent
experiments. The purity of SP cells was 97–99% and the purity of NSP
cells was 96%.
We analyzed the cell surface phenotype and epithelial origin of SP
cells using CD44 and pan-cytokeratin staining respectively. A higher
expression of CD44 was observed in SP cells as compared to NSP cells
in both T24 (Fig. 1B) and UM-UC-3 cell lines (Sup Fig. 1B). Both SP
and NSP cells expressed pan-cytokeratin (Fig. 1B).
3.2. Stem cell-like characteristics and drug resistance in SP cells
Fig. 2A shows the expression of the stem cell (SOX-2, KLF-4, OCT-4
and NANOG) and drug resistance genes (MDR1 and ABCG2) in bulk
T24, NSP and SP cells. We observed that stem cell associated gene ex-
pression was highest in SP cells (p b 0.001) as compared to both NSP
and bulk T24 (Fig. 2A) and UM-UC3 (Sup Fig. 1C) cells. The mRNA ex-
pression of ABCG2 and MDR1 was also found to be signiﬁcantly higher
in SP cells (p b 0.001) as compared to NSP and bulk T24 cells. The effect
of the anticancer agents such as cisplatin, gemcitabine andmitomycin on
cell survival was conﬁrmed byMTT assay (Fig. 2B). Both SP and NSP cells
were exposed to cisplatin/gemcitabine/mitomycin in a time (0–48 h)
and dose (5–20 μM) dependent manner (Sup Fig. 2). SP cells treated
with cisplatin (20 μM)/gemcitabine (10 μM)/mitomycin (5 μM) for 24
h showed lower cell death (11± 0.04%, 13± 0.03% and 17±0.023% re-
spectively) as compared toNSP cells (24± 0.012%, 32±0.03% and 29±
0.042% respectively) at the same drug concentration, indicating that SP
cells exhibit stronger resistance as compared to NSP cells (Fig. 2B). This
dose was selected for all subsequent experiments.
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Fig. 7.Autophagy inhibition potentiates the cytotoxic effect of chemotherapeutic agents. FACS images showing subG1 analysis formonitoring apoptotic population in tumor spheroid cells
treated with cisplatin/gemcitabine/mitomycin with or without Wm for 24 h. Lower panel shows the percentage of subG1 SP and NSP cells analyzed and quantiﬁed with Cell Quest Pro
software. Cells in complete media were taken as control. Each experiment was repeated three times. Values are expressed as mean ± SEM. *, p b 0.05 NSP vs. MTS; #, p b 0.05 cisp/
gem/mito vs. cisp + Wm/gem + Wm/mito +Wm.
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both NSP and bulk cells in T24 (Fig. 3A) and UM-UC-3 (Sup Fig. 3A).
ROS production in T24 cells was further validated by the measurement
of GSSG/GSH ratio which showed a signiﬁcantly higher expression
(p b 0.05) in SP cells as compared to NSP cells (Fig. 3B). SP cells showed
a lower metabolic activity in terms of low mitochondrial mass and
lower ATP levels than NSP cells (Sup Fig. 3B, C).Fig. 6. Autophagy is induced by chemotherapeutic agents in tumor spheroids. (A) Images showi
withoutWm (200 ng/ml) for 24 h. Side panel shows themean ﬂuorescence intensity in cells tre
in the presence of Wm. (B) Immuno-staining with anti-LC3 antibody. Quantitation was done b
(Olympus) in side panel. (C)Western blot analysis of LC3 expression in cells derived from tumo
out Wm (200 ng/ml) for 24 h. Each experiment was repeated three times. Cells in complete m
treatment; **, p b 0.01 control vs. treatment; #, p b 0.01 treatment vs. treatment +Wm.3.3. Spheroid forming ability of SP cells
The SP cells could form tumor like spheroids when plated in condi-
tioned culture medium in non-adherent plates. The spheroids grew to
more than 100 μm in diameter in T24 (Fig. 4) and UM-UC-3 (Sup
Fig. 4) cells. A size of 60 μm was selected as a cut-off for counting the
number of spheroids as described previously [18]. The mean numberng acridine orange stained autophagosomes in cells derived from tumor spheroids with or
atedwith cisplatin (20 μM) or gemcitabine (10 μM) ormitomycin (5 μM)which decreased
y counting the number of LC3 dots/micrograph and was calculated in FV10-ASM software
r spheroids with cisplatin (20 μM)/gemcitabine (10 μM)/mitomycin (5 μM)with or with-
edia were taken as control. All values are expressed as mean ± SEM. *, p b 0.05 control vs.
Fig. 8. Inhibition of autophagy increases apoptotic response in tumor spheroid. (A)Western immuno-blot showing silencing of BECN1 gene expression in T24 cells. Starvation induced by
HBSS treatment for 24 h was taken as positive control. (B) Micrographs show the size of tumor spheroids formed by the SP cells on silencing of BECN1 expression after 2 and 4 days along
with respective controls. The quantiﬁcation of the mean size and number of tumor spheroids was done after 4 days and represented in the lower panel (scale bar—70 μm). (C) FACS
quadrants show annexin/7-AAD staining at 24 h of treatment of chemotherapeutic agents in BECN1-silenced tumorisphere cells. Quantiﬁcation of the apoptotic cell death (annexin+
and annexin/7AAD+ cells) was done with FlowJo software. (D) Western blots show the expression of apoptotic and anti-apoptotic proteins in cells derived from tumor spheroids.
(E) FACS cytograms show DCFH-DA staining for ROS measurement at 24 h of treatment in BECN1-silenced tumorisphere cells. Bar graph represents the mean ﬂuorescent intensity of
these cells on treatment with cisplatin, gemcitabine and mitomycin. Each experiment was repeated three times. Values are expressed as mean ± SEM. *, p b 0.05; **, p b 0.01 control-
siRNA vs. BECN1-siRNA. Cisp = cisplatin; Gem= gemcitabine; Mito = mitomycin.
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0.3/1000 in T24 (Fig. 4) and UM-UC-3 cells (Sup Fig. 4) respectively
after 9 days. However, NSP cells could not form spheroids under similar
conditions (Fig. 4, Sup Fig. 4). To demonstrate the self-renewal capacity
of spheroids in vitro, we serially passaged them and found that they
could retain the spheroid forming capability for more than 12 genera-
tions (Sup Fig. 5).
3.4. Side population shows greater autophagic ﬂux
About a two fold increase in the number of autophagosomeswas ob-
served in tumorispheres in the absence of autophagy induction in bothT24 (Fig. 5A) and UM-UC-3 cells (Sup Fig. 6A). Immuno-staining of LC3
initially showed diffuse staining in both NSP and bulk T24 cells which
concomitantly increased when starvation was induced with HBSS.
Interestingly, tumor spheroid cells from SP showed higher number
(120 ± 0.4) of punctate LC3 staining as compared to NSP (60 ± 0.45)
and T24 (80 ± 0.39) cells at all times both before and after starvation
was induced (Fig. 5B).
We also used rapamycin, mTOR inhibitor for pharmacological induc-
tion of autophagy and observed that it had no effect on cell viability
(Fig. 5C, D). On the other hand, inhibition of autophagywith chloroquine
(CQ) signiﬁcantly increased cell death in these cells (56 ± 0.5, Fig. 5F).
Similar observations were found in SP of UM-UC-3 cells (Sup Fig. 6B, C).
Fig. 8 (continued).
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higher expression of Beclin1 and Atg7 with concomitant degradation
of p62 was found in cells derived from tumor spheroids as compared
to NSP and bulk T24 cells (Fig. 5E). ER stress with tunicamycin led to
an increase in the expression of Beclin1, Atg7 and p62 degradation
(Fig. 5E). Co-localization experiments were performed using mitochon-
drial membrane marker TOM, and LC3 as well as ER membrane marker
calreticulin and LC3. In the presence of antimycin, TOM and LC3 were
co-localizedwhile calreticulinwas co-localizedwith LC3 in the presence
of tunicamycin (Fig. 5F).
3.5. Autophagy provides resistance against chemotherapy in tumor
spheroids
The autophagic response towards the chemo-therapeutic drugs cis-
platin, gemcitabine and mitomycin was assessed by measuring the
autophagosomes in cells derived from tumor spheroids. Autophagosomes
were found to be signiﬁcantly increased in the presence of all the three
chemo-therapeutic agents (Fig. 6A) and decreasedwithWm treatment.
Immuno-staining (Fig. 6B) as well as Western immuno-blotting
(Fig. 6C) experiments in cells treated with cisplatin/gemcitabine/
mitomycin showed a higher expression of LC3 protein in cells derived
from tumor spheroids compared to NSP cells. A signiﬁcant increase in
autophagic response towards cisplatin, gemcitabine and mitomycin
was also observed in UM-UC-3 cells as evident from the bar graph
(Sup Fig. 7A).
On subG1 analysis cells from tumorispheres showed 6–9% apo-
ptotic cells in the presence of cisplatin/gemcitabine/mitomycin
alone, which increased up to 40–50% (Fig. 7) in the presence of
Wm. Treatment with cisplatin/gemcitabine/mitomycin caused
24–32% apoptosis in NSP cells and Wm had no signiﬁcant effect
on apoptosis in these cells (Fig. 7). Annexin-V/7-AAD staining
also conﬁrmed that autophagy inhibition with Wm led to increase
in apoptotic population in tumorisphere of UM-UC-3 cells. Thepercentage of apoptotic population was found to increase up to
50–63% in the presence of Wm (Sup Fig. 7B).3.6. Autophagy inhibition potentiates the cytotoxic effect of chemotherapeutic
agents
BECN1 si-RNA transfection was conﬁrmed by immuno-blotting
(Fig. 8A). SiRNA-mediated silencing of BECN1 in T24 cells led to the re-
duction of the size (20 ± 0.02 μm, Fig. 8B) as well as the number (19 ±
0.04/1000 cells, Fig. 8B) of spheres obtained from SP cells as compared
to control siRNA. Similar results were found in SP of UM-UC-3 cells
(Sup Fig. 8A, B). The addition of BECN1-siRNA with cisplatin or
gemcitabine or mitomycin increased the cell death up to 55–72% in
T24 (Fig. 8C) and 59–70% in UM-UC-3 cells (Sup Fig. 8C) as compared
to chemotherapeutic agents alone. Further we investigated the levels
of different anti- and pro-apoptotic proteins during autophagy inhi-
bition. Treatment with cisplatin in cells derived from tumor spheroid
had no effect on the expression of anti-apoptotic proteins Bcl-2, Bcl-
XL, c-IAP1/2 and XIAP. However, Wm along with cisplatin decreased
the expression of Bcl-2, Bcl-XL, c-IAP1/2 and XIAP, thus indicating in-
creased cell death (Fig. 8D). Gemcitabine and mitomycin treatments
also had no effect of anti-apoptosis protein expression, but autopha-
gy inhibition byWm along with gemcitabine or mitomycin led to the
decrease of the expression of Bcl-2, Bcl-XL, c-IAP1/2 and XIAP
(Fig. 8D). Treatment of cisplatin/gemcitabine/mitomycin had no signiﬁ-
cant effect on the pro-apoptotic proteins, and Bim and Bax expression
in cells derived from tumor spheroid. However, the expression of Bim
and Baxwas found to increase in the presence ofWmalongwith cisplat-
in or gemcitabine or mitomycin (Fig. 8D). In BECN1 knockdown
tumorisphere cells, ROS levels were higher in the presence of cisplatin/
gemcitabine/mitomycin (p b 0.05, Fig. 8E) as compared to their respec-
tive controls. Similar results were obtained in UM-UC-3 cells (Sup
Fig. 8D).
Fig. 8 (continued).
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spheroids
Immunoblot analysis revealed that caspase-9 was not activated in
the presence of cisplatin/gemcitabine/mitomycin alone. Cells in which
BECN1 expression had been silenced showed activation of caspase-9,
when treated with cisplatin/gemcitabine/mitomycin. However, neither
caspase-12 nor caspase-8 was activated in the presence of cisplatin/
gemcitabine/mitomycin alone in these cells (Fig. 9). To conﬁrm the in-
volvement of the intrinsic apoptotic pathway, we checked the
cytochrome-c (Cyt-C) release on treatment with chemotherapeutic
agents in these cells. We found that Cyt-C was released only in
tumorisphere cells where BECN1 expression had been silenced
(Fig. 9). Treatment with cisplatin/gemcitabine/mitomycin alone had
no effect on the activation of caspase-3 as well as on PARP cleavage in
tumorisphere derived cells. However, caspase-3 activation and PARP
cleavage were evident when autophagy was inhibited in these cells
with BECN1-siRNA (Fig. 9).4. Discussion
A sub-population of tumor-initiating or -sustaining cells has been
identiﬁed in various solid tumors which grow more readily in an
anchorage-independent manner, over-express stem cell-associated
markers and aremore resistant to drugs used in the treatment of cancer
[21]. One of the methods that have been successfully used to isolate
such putative tumor stem cells is differential Hoechst dye uptake [22].
Using this approach, we have identiﬁed a subpopulation of cells termed
“side population” (SP) from bladder cancer cell lines, T24 and UM-UC-3.
These cells were found to be more tumorigenic than non-side popula-
tion (NSP), which formed the bulk of tumor cells. Our results showedthat SP cells could form clonal, non-adherent 3-D spheres, when
allowed to grow in conditioned media. Moreover, the tumor initiating
capability was not decreased as the spheres were passaged. We also
found that SP cells from tumorispheres, regenerated a population of
cells composed of both SP and non-SP, resembling the original unsorted
population, thus showing repopulating capacities similar to stem cells.
This ﬁnding implies that SP cells may undergo asymmetrical division
to self-renew and generate heterogeneous phenotypes of low-
tumorigenic cells, like NSP cells that form the bulk of the tumor.We ob-
served that the SP cells had a higher expression of CD44, a potential
marker of cancer stem cells (CSCs), as compared to the parental cells
in both T24 and UM-UC-3. CD44 has been reported to be involved in
cancer cell migration, proliferation and metastasis [23]. SP cells isolated
in our study showed a higher expression of stem cell marker i.e. SOX-2,
OCT-4, NANOG, and KLF-4 than NSP cells, indicating that the SP cells
possess stem cell like characteristics. It is generally agreed that, like all
stem cells, the tumor sphere forming cells or CSCs are capable of prolif-
eration and self-renewal and possess higher tumorigenicity [24]. A
higher expression of ATP-binding cassette, subfamily G, member 2
(ABCG2) and MDR1 was observed in SP compared to NSP cells. The
ABCG2 gene is highly expressed in the plasma membrane of several
drug resistant cancer cell lines and has been shown to transport antitu-
mor drugs such as mitoxantrone, topotecan and doxorubicin [25]. A
higher expression of MDR1, another potential drug resistant gene, was
also reported in various other cancer cells including renal cell carcino-
ma, colon adenocarcinoma, hepatocellular cancer and bladder cancer
[26]. On this basis, we hypothesized that the SP cells isolated from the
bladder cancer cell line may survive conventional chemotherapy and
regenerate a cancer population, leading to relapse. Reduced metabolic
activity in T24 SP cells indicates a higher ROS scavenging potential in
these cells which may aid in cell survival during later stages. The low
level of ROS as observed in the SP cells may help to maintain their
Fig. 9. Inhibition of autophagy leads to intrinsic apoptotic cell death in tumor spheroid.
Western immunoblot expression of the caspases (caspase-9, -8, -12, and -3) in BECN1-
siRNA transfected tumorisphere cells treated with cisplatin/gemcitabine/mitomycin for
24 h. Cytochrome-c release was determined in the cytosolic fraction. Activation of
caspases was indicated by inhibition of their pro-caspase form or cleavage of PARP. Each
experiment was repeated three times.
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duction and high GSSG/GSH ratio may also show higher radio and
chemo-resistance. Our report is consistent with a previous study
which showed that low levels of ROS in glioma stemcells help to protect
against radiotherapy induced DNA damage [27]. Interestingly, there are
subsets of CSCs in human and mouse breast tumors containing lower
ROS levels than the corresponding non-tumorigenic cells. This low
level of ROS seems to be associated with a high expression of ROS scav-
enging molecules, which may also contribute to tumor radio/
chemoresistance [28]. The efﬁcacy of cancer therapies including radia-
tion therapy and anticancer drugs is partly attributed to the production
of ROS and consequent induction of oxidative stress in cancer cells [29].
The lower level of ROS in SP cells may also help to sustain their long
term self-renewal and survival during anticancer therapies. Low levels
of ROS in SP cells probably regulate their stem cell like phenotype in
the niche.
In our experiments, we found substantial resistance of SP cells to
standard chemotherapy in bladder cancer. Even at a very high concen-
tration (10–25 μM), gemcitabine, mitomycin and cisplatin were not
able to induce apoptosis in these cells. This ﬁnding is consistent with a
previous report which showed that side population deﬁnes a class of
cancer stem cells with inherently high resistance to chemotherapeutic
agents that should be targeted during the treatment of malignant dis-
ease [30].
Despite advances in the early detection of bladder cancer, as well as
the development of new therapies that target a speciﬁc molecular
pathway, mortality rate from cancer is still high. Furthermore, bladder
cancer patientsmay present with distant metastasis after an apparentlysuccessful treatment of initial malignancy, followed by a period of dor-
mancy. Thus, in order to reduce the morbidity and mortality from can-
cer, it is necessary to gain a greater understanding of metastasis and
clinical dormancy, as well as the molecular factor that contributes to
this process. In the last decade, the role of autophagy in resistance to
chemotherapy has been explored in detail. Since autophagy has been
observed to play a more crucial role in cancer cell homeostasis than
previously conceived, understanding how the cancer cells undergoing
autophagy cross the threshold from cell survival to cell death
during drug treatment is important for identifying more potent drug
targets.
A number of antineoplastic therapies including radiation therapy
and chemotherapy have been observed to induce autophagy as a pro-
tective and pro-survival mechanism in human cancer cell lines [31].
Thus, inhibition of autophagy may lead to increased cell death and dis-
semination of tumor growth. In this context, combining anticancer
drugs with appropriate autophagy inhibitor has a promising prospect
in chemotherapy. Our data suggests that autophagy has a key role in
the maintenance of the SP subpopulation in bladder cancer cells since
autophagic ﬂux was signiﬁcantly higher in the SP compared to NSP
cells. The autophagy-mediated cell survival in response to rapamycin
and cell deathwith CQ further suggests the functional role of autophagy
in SP cell viability. Pharmacological inhibition of autophagy has been re-
ported with Wm [32–35] and CQ [36,37]. We observed a signiﬁcant in-
crease in the cytotoxicity of the chemotherapeutic drugs when given in
combination with Wm. In order to further conﬁrm the effect of
autophagy inhibition, we used siRNA to knock down ATG gene,
BECN1, implicated in the initiation of autophagic pathway. The impor-
tance of autophagy in tumorigenicity was substantiated by the reduced
number of tumor spheroids from the SP cells when autophagy was
inhibited by silencing BECN1 gene. Therefore, modulation of autophagy
may represent a major impediment to a successful cancer therapy. Our
data indicates that the autophagy induced by cisplatin, gemcitabine and
mitomycin, delayed the cytotoxic effect of chemotherapeutic agents.
Autophagy inhibitor or siRNA-mediated depletion of BECN1 given in
combination with cisplatin, gemcitabine or mitomycin inhibited the
proliferation of tumor spheroids. It also triggered cell death to a greater
extent than cisplatin/gemcitabine/mitomycin alone or control-siRNA.
Our ﬁndings suggested that down-regulation of BECN1 decreased au-
tophagy and inhibited tumorigenesis. Thus, autophagy may be required
for the maintenance of tumor spheroids and provide resistance to
chemotherapy. Cell death induced via inhibition of autophagy was cor-
related with higher production of ROS in the presence of BECN1-siRNA.
Our ﬁnding is consistent with other studies which showed that in
preclinical models, inhibition of pro-survival autophagy by genetic or
pharmacological means killed the tumor cells and triggered the apopto-
tic cell death [38]. Similar observations were obtained in another
bladder cancer cell line UM-UC-3, which further substantiates our results.
Autophagy enhances the metastatic potential of carcinoma cells by
supporting anoikis resistance and tumor dormancy during tumor cell
dissemination. It has been suggested that autophagy may inﬂuence
apoptosis in various cancerous cells. However, the molecular interplay
between these two different pathways seems to be very complex and
has not been fully understood. While autophagy induces cell death in
human glioma cell lines [39], several reports have suggested that
autophagy inhibition increases caspase mediated cell death in various
cancer cells [40]. In the present study, activation of caspase-8 was not
observed, which excluded the involvement of extrinsic apoptotic path-
ways. In addition, to seek the possibility of ER stress induced apoptosis,
caspase-12 was measured and we observed that like caspase-8,
caspase-12 was also not playing any role in apoptosis induced by au-
tophagy inhibition. We found that autophagy inhibition by BECN1-
siRNA along with cisplatin/gemcitabine/mitomycin led to a release of
Cyt-C in cytosol which in turn activated caspase-9, caspase-3 and
PARP cleavage. These ﬁndings indicated that autophagy inhibition led
to intrinsic apoptotic cell death in the tumorisphere cells obtained
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tumor-initiating cell population will help us to reﬁne the stimuli
that force these cells to die, thus accelerating the development of a
more effective treatment for cancer.
5. Conclusions
In the present study, we found that high drug efﬂux capacity of SP in
bladder cancer cell lines correlates with the strong expression of drug
transporter proteins. We analyzed the autophagy in SP cells as well as
in spheroid culture. We found that the greater autophagic ﬂux in SP
cells as compared to NSP correlated with a high expression of autopha-
gic markers in tumor spheroids suggesting that the maintenance and
tumorigenicity of SP might be dependent on autophagy. Therefore, a
better understanding of the autophagic pathway in SP cells would
help us to design better inhibitors for preventing drug resistance in
bladder cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.07.007.
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